- Title: Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive
   treatment among people living with HIV in Uganda
   Authors: Jillian L. Kadota<sup>\*1,2</sup>, Allan Musinguzi<sup>\*3</sup>, Hélène E. Aschmann<sup>1,2</sup>, Lydia Akello<sup>3</sup>, Fred Welishe<sup>3</sup>,
   Jane Nakimuli<sup>3</sup>, Christopher A. Berger<sup>1,2</sup>, Noah Kiwanuka<sup>4</sup>, Patrick PJ Phillips<sup>1,2</sup>, Achilles Katamba<sup>5,6</sup>,
- 5 David W. Dowdy<sup>7</sup>, Adithya Cattamanchi<sup>\*\*2,9</sup>, Fred C. Semitala<sup>\*\*3,8,10</sup>
- Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San
   Francisco CA USA
- 8 2. Center for Tuberculosis, University of California San Francisco, San Francisco CA USA
- 9 3. Infectious Diseases Research Collaboration, Kampala, Uganda
- 10
   4. Department of Epidemiology and Biostatistics, School of Public Health, Makerere University
   11
   College of Health Sciences, Kampala, Uganda
- S. Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of
   Health Sciences, Kampala, Uganda
- 14 6. Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda
- 15 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
- 16 USA
- 17 8. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- 18 9. Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Orange
- <sup>19</sup> CA USA
- <sup>20</sup> 10. Makerere University Joint AIDS Program, Kampala, Uganda
- 21 \*Contributed equally as first authors
- 22 \*\*Contributed equally as senior authors
- 23 Corresponding author:
- 24 Adithya Cattamanchi
- 25 University of California Irvine
- $26 \qquad \textbf{333 City Blvd. West, Suite 400}$

- Orange, CA 92868
- Summary (40 words): 3HP is being rolled out for TB prevention in high burden countries. We describe
- the incidence and clinical management of adverse events in a real-world clinical setting among people
- living with HIV participating in a pragmatic implementation study in Uganda.
- Number of figures/tables: 3

## 53 ABSTRACT

54 **Background**: Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and 55 rifapentine (3HP), are increasingly used in high TB-burden countries. Despite established safety and 56 tolerability in efficacy trials, 3HP-related adverse events (AE) could differ in routine settings. Real-world 57 data on AE type, frequency, and timing is crucial for health systems considering 3HP programmatic scale-58 up.

59 **Methods:** We reviewed AEs among people living with HIV (PLHIV) participating in a pragmatic 60 implementation trial of facilitated 3HP taken by directly observed therapy (DOT) or self-administered 61 therapy (SAT) in Kampala, Uganda, and classified them using the Common Terminology Criteria for 62 Adverse Events. We assessed AE timing and summarized related clinical actions including lab tests, 63 diagnoses made, medications prescribed, and treatment interruptions.

64 Results: Among 1655 PLHIV treated between July 2020-September 2022, 270 (16.3%) reported 451 65 events; main issues included general (7%), nervous system (6%), musculoskeletal (5%), gastrointestinal 66 (5%), and dermatologic (3%) disorders. Most (61%) occurred within 6 weeks of initiating 3HP. Among 67 those with events, 211 (78%) required further clinician evaluation, 202 (75%) required laboratory testing, 68 102 (38%) had medications prescribed, 40 (15%) had treatment paused, and 14 (5%) discontinued 3HP. Women, those multidimensionally impoverished, and DOT recipients were more likely to report an AE. 69 70 SAT users and later enrollees were more likely to have 3HP interrupted or stopped due to an AE. 71 Conclusions: In a routine setting, 3HP was safe with 16% of PLHIV reporting AEs and only 3% requiring 72 temporary or permanent treatment interruption. These findings support 3HP expansion in routine

73 HIV/AIDS care settings for TB prevention.

### 74 BACKGROUND

75 Prevention of tuberculosis (TB) is an urgent priority for global TB programs (1,2) and scale-up of TB 76 preventive treatment (TPT) in high TB burden countries is critical for achieving ambitious TB elimination 77 goals by 2030. Short-course regimens, such as 12 weekly doses of isoniazid and rifapentine (3HP), are 78 now recommended as an option for TB prevention based on several trials demonstrating efficacy, safety, 79 and improved completion relative to the traditional standard of six to nine months of daily isoniazid (3-6). 80 However, data on the safety of 3HP in routine care settings remain sparse and are needed to help 81 policymakers better anticipate the resources required for adverse event management as 3HP is rolled 82 out for TB prevention.

83

84 Here, we describe adverse events reported in the 3HP Options Trial, a pragmatic implementation trial 85 that delivered 3HP to adult PLHIV accessing routine clinical HIV/AIDS care in Kampala, Uganda via 86 facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT) or participant 87 choice between facilitated DOT and SAT. In this pragmatic trial, routine health workers were responsible for monitoring, evaluating, and providing care to participants receiving 3HP treatment. We previously 88 89 reported that treatment completion was high overall (94%), and similar across trial arms (95%, 92% and 90 94% for facilitated DOT, facilitated SAT and Choice, respectively) (7). Our objective here was to 91 characterize the frequency, type and severity of adverse events, and secondarily to identify demographic 92 and clinical characteristics associated with reported adverse events and with 3HP treatment interruption 93 or discontinuation.

94

#### 95 **METHODS**

96 Study design and population

97 The study design and population, including eligibility criteria, are described in detail elsewhere (7,8).
98 Briefly, the *3HP Options Trial* was a pragmatic trial of 3HP delivery strategies among adult (≥18 years)
99 PLHIV accessing care at the Mulago Immune Suppression Syndrome (IS;) clinic, the largest HIV/AIDS

100 clinic in Uganda. Eligible PLHIV were randomized to one of three delivery strategies: facilitated directly 101 observed therapy (DOT), facilitated self-administered therapy (SAT), or participant choice between 102 facilitated DOT and SAT. After taking the first dose in person, participants taking 3HP via facilitated DOT 103 returned to the clinic weekly for the remaining 11 doses, whereas those taking 3HP via facilitated SAT 104 had scheduled clinic visits for in-person dosing at weeks 6 and 12 only.

105

#### 106 Adverse events reporting and assessment

107 Prior to 3HP dosing at scheduled clinic visits, a Mulago ISS clinic pharmacy technician used a 108 standardized form to screen participants for the presence/absence of any side effect and if present to 109 screen for each of the following commonly reported side effects of 3HP treatment: 1) loss of appetite, 2) 110 nausea or vomiting, 3) yellow eyes or skin, 4) abdominal pain, 5) diarrhea, 6) rash/hives, 7) fever or chills, 111 8) dizziness/fainting, 9) numbness or tingling, 10) headache, 11) joint pain, 12) itching, 13) weakness, or 112 14) other (with the option to specify). Following self-administered doses, participants taking 3HP by SAT 113 could report that they were feeling unwell via weekly two-way toll-free interactive voice response (IVR) 114 phone calls sent by a digital adherence monitoring platform used for the study (99DOTS, Everwell Health 115 Solutions, Bengaluru, India). Mulago ISS clinic pharmacy technicians made phone calls to participants 116 who reported feeling unwell and screened for side effects using the same standardized form used during 117 in-person visits. In addition, all participants were instructed that they could visit or call the clinic at any 118 time during open hours if they felt unwell, without the need to wait for their next scheduled appointment. 119 Thus, participants could report adverse events at scheduled clinic visits for in-person dosing, IVR phone 120 calls (SAT only), or through unscheduled phone calls and clinic visits.

121

Mulago ISS clinic pharmacists recorded the presence or absence of each common side effect using the standardized form. The form also included fields to specify if the patient was referred for further evaluation by a clinician, if or which laboratory tests were ordered, results of any laboratory testing, medications prescribed because of adverse event(s) reported, and details about treatment interruption or permanent

discontinuation. Of note, Mulago ISS clinic pharmacists made all decisions to refer participants with suspected adverse events to a routine (*i.e.*, non-study) clinician who then managed all activities related to adverse events assessment, including additional clinical or laboratory evaluation and decisions to hold or discontinue 3HP treatment.

130

131 Statistical analysis

At the conclusion of participant follow-up, two analysts (JLK and HEA) independently re-coded all adverse events initially recorded as "other" (*e.g.*, those not in pre-defined categories and/or those with different spellings). The same analysts then independently re-categorized all adverse events using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (9). Two research staff with medical training (AM and LA) adjudicated disagreements in categorizations.

137

Time to adverse event onset was calculated by taking the difference between the date of first report of the adverse event and the date of 3HP initiation. We quantified adverse events that resulted in referrals, additional lab tests ordered, diagnoses made, and medications prescribed using counts and percentages, and compared across study arms using Fisher's exact tests. Finally, we used multivariable logistic regression to explore the clinical and sociodemographic variables associated with reporting any adverse event and discontinuing treatment because of an adverse event. Variables included in final multivariate models were those determined *a priori* based on relationships identified in the literature (10,11).

145

The trial is registered at ClinicalTrials.gov (NCT03934931) and was approved by the ethical committees at the University of California San Francisco, Makerere University College of Health Sciences School of Public Health, and the Uganda National Council for Science and Technology. All participants gave written informed consent for study participation.

150

151 **RESULTS** 

152	Between July 13, 2020, and July 8, 2022, we enrolled 1,655 eligible PLHIV. Follow-up continued until
153	September 29, 2022. In the Choice arm, 370 participants (67.0%) initially preferred facilitated DOT; thus,
154	921 participants received 3HP via facilitated DOT, and 734 participants via facilitated SAT. Median
155	participant age was 42 years (interquartile range [IQR]: 36-48); 1,122 (67.8%) were female; and median
156	time on ART was 9.0 years (IQR: 5.6-12.5), with no differences by treatment strategy (Table 1).

157

158 Table 1. Participant characteristics comparing those taking 3HP via directly observed therapy versus self-

administered therapy (n=1,655).<sup>1</sup>

	DOT (n=921)	SAT (n=734)
Age	41.9 (9.4)	42.6 (9.2)
Female sex	614 (66.7)	508 (69.2)
Education		
None	71 (7.7)	68 (9.3)
Primary	452 (49.1)	330 (45.0)
Secondary	335 (36.4)	265 (36.1)
Tertiary/Vocational	37 (4.0)	48 (6.5)
University/Graduate School	26 (2.8)	23 (3.1)
Employment status <sup>2</sup>		
Unemployed	129 (14.0)	96 (13.1)
Hired worker	105 (11.4)	99 (13.5)
Self-employed worker	445 (48.3)	372 (50.7)
Temporary/informal worker	233 (25.3)	163 (22.2)
Other	3 (0.3)	2 (0.3)
Multidimensional Poverty Index <sup>3</sup>		
Not vulnerable to multidimensional poverty	378 (41.0)	341 (46.5)
Vulnerable to multidimensional poverty	332 (36.1)	251 (34.2)
Multidimensionally poor	167 (18.1)	118 (16.1)
Severely multidimensionally poor	44 (4.8)	24 (3.3)
Reported an adverse event while taking 3HP	175 (19.0)	95 (12.9)
Prior TB infection	165 (17.9)	136 (18.5)

Time (years) on ART	8.8 (4.5)	8.9 (4.4)		
ART Regimen				
Dolutegravir + Lamivudine + Tenofovir	804 (87.3)	647 (88.2)		
Tenofovir + Lamivudine + Efavirenz	65 (7.1)	46 (6.3)		
Other <sup>4</sup>	52 (5.6)	41 (5.6)		
Viral load <1000 copies/mL⁵	906 (98.4)	727 (99.1)		
Body Mass Index (kg/m <sup>2</sup> )	25.9 (5.8)	26.3 (5.4)		

160 ART=antiretroviral therapy; DOT=directly observed therapy; SAT=self-administered therapy; TB=tuberculosis 161 1. Data are n (%) or mean and standard deviation (SD).

162 2. n=8 missing.

163 3. The global multidimensional poverty index (MPI) examines deprivations across 10 indicators in dimensions of 164 health, education, and standards of living, with those deprived in one-third or more of the 10 indicators counted 165 as being multidimensionally poor. MPI scores can range from 0 to 1 and are classified as not vulnerable to 166 multidimensional poverty (MPI score: 0-0.19), vulnerable to multidimensional poverty (MPI score: 0.20-0.32), 167 multidimensionally poor (MPI score: 0.33-0.49) and severely multidimensionally poor (MPI score: ≥0.50).

168 4. Other regimens included Abacavir + Lamivudine + Dolutegravir (n=82), Lamivudine + Zidovudine + Dolutegravir 169 (n=8), Lamivudine and Zidovudine 150mg/300mg tablet (n=1), Abacavir + Lamivudine + Efavirenz (n=1).

170 5. Suppressed defined as <1000 copies/mL according to Ugandan guidelines; n=2 missing.

171

172 Adverse event frequency, typology and timing

173 Overall, 270 (16.3%) participants reported at least one adverse event over the course of 3HP treatment

174 (Figure 1), including 175 (19.0%) people receiving 3HP via DOT and 95 (12.9%) receiving 3HP via SAT

175 (Table 1). Participants in the DOT arm, those who were female, or multidimensionally poor people were

176 more likely to report any adverse event, associations confirmed in multivariable logistic regression models

177 (adjusted odds ratios [aORs]=1.59, 95% confidence interval (CI): 1.21, 2.09; p=0.001 for DOT; 1.61, 95%

178 Cl: 1.05-2.01; p=0.02 for female sex; and 1.40, 95% Cl: 1.00, 1.96; p=0.05; for poverty or severe

179 multidimensional poverty) (Supplement Table 1).

180

#### 181 Figure 1. Frequency of reported adverse events during 3HP treatment according to Common Terminology

182 Criteria for Adverse Events (version 5.0) categories.



183

184 Shown are the number and percentage of participating PLHIV taking 3HP for prevention of tuberculosis who 185 reported adverse events in each category. The total number of participants assessed for adverse events in the 3HP 186 Options Trial was 1,655, as indicated by the dashed vertical line.

- 187
- 188

189 The most frequently reported adverse events (reclassified according to CTCAE, **Supplement Table 2**)

190 were general disorders such as fever or flulike illness (n=116 PLHIV, 7% of all study participants),

191 nervous system disorders (n=103, 6%), musculoskeletal disorders (n=87, 5%), gastrointestinal disorders

192 (n=82, 5%), or dermatologic disorders (n=56, 3%; Figure 1). Hepatobiliary disorders were infrequent,

193 with only seven participants (0.4%) reporting related adverse events.

194

195 Among participants who had an adverse event, the median time to an adverse event was 35 days (IQR:

196 14-49). There was a significant difference in the survival curves comparing time to an adverse event

- 197 between participants receiving 3HP via DOT vs. SAT, with people receiving 3HP by SAT less likely to
- report an adverse event (log-rank p=0.001; **Figure 2**).
- 199
- 200 Figure 2. Time to first adverse event experience stratified by 3HP delivery strategy (facilitated DOT vs.
- 201 facilitated SAT).



202

203

204 DOT=directly observed therapy; SAT=self-administered therapy

The solid horizontal stepped line represents the cumulative probability of not have an adverse event among participants receiving 3HP via facilitated directly observed therapy (DOT), and the dashed horizontal stepped line represents those receiving 3HP via facilitated self-administered therapy (SAT). The numbers outside of parentheses at the bottom of the figure represent the total number of participants at risk, while the numbers in parentheses represent the number censored at the time interval indicated.

- 210
- 211 Additional health care utilization for adverse events
- Among those reporting adverse events, 211 (78.1%) were referred to a clinician for further evaluation,
- 213 202 (74.8%) required laboratory testing, and 102 (37.8%) had medication(s) prescribed. The most

common types of lab tests ordered included urinalysis (n=77), malaria tests (n=59), and blood glucose tests (n=24). For the 209 total lab tests ordered, 35 diagnoses were made (**Supplement Figure 1**). The proportion referred to a clinician was similar among those taking 3HP via facilitated DOT vs. facilitated SAT (p=0.22). Those who took 3HP by facilitated SAT were more likely to have laboratory testing ordered (46.3% vs. 33.1%, p=0.04), whereas those who took 3HP by facilitated DOT were more likely to be prescribed medications to treat adverse events (78.9% vs. 67.4%, p=0.04).

220

Among the 270 PLHIV reporting adverse events, 40 (14.8%) had treatment held temporarily and 14 (5.1%) had treatment permanently discontinued by a Mulago ISS clinician (<1% of PLHIV taking 3HP overall). Participants taking 3HP via SAT (28.4% vs 15.4%) and participants enrolled after the first six months of the study (22.1% vs 15.7%) were more likely to have 3HP treatment held or discontinued due to an adverse event (**Supplement Table 3**).

226

#### 227 **DISCUSSION**

228 Growing interest in the use of short-course TPT regimens such as 3HP for TB prevention requires better 229 data on adverse events to inform planning for programmatic scale-up. In this pragmatic trial of 1,655 230 PLHIV taking 3HP in Kampala. Uganda with minimal loss to follow-up prior to treatment completion, the 231 frequency of adverse events was low, with only 16% of participants experiencing any adverse event. 232 Adverse events were effectively managed by routine healthcare providers, with no deaths, only 3% 233 requiring treatment interruption, and <1% requiring treatment discontinuation. These data add to the 234 existing body of literature demonstrating 3HP safety and tolerability as some of the first data to come 235 from a high-burden, programmatic context, and may provide reassurance to programs planning for or 236 considering short-course regimens as alternatives for TPT in similar settings.

237

The frequency of adverse events reported in this pragmatic trial were comparable to what has been documented in other recent studies of 3HP implementation in high burden settings (12,13), but was

240 substantially lower than what was reported from a multi-country randomized trial of 3HP (14), in which 241 77% reported one or more symptoms at any time during treatment (11). However, data from the only 242 participating African country in that trial included only a small number of participants (n=83). Additionally, 243 treatment dosing/supervision, study follow-up, and adverse event management in that trial were 244 managed by trained research staff. Here, we provide data from people taking 3HP in the context of routine 245 HIV/AIDS care, which may be a more accurate reflection of what can be expected in other programmatic 246 settings. In this context, although the majority of participants who reported an adverse event were 247 prescribed medications for those symptoms, the burden of laboratory testing was relatively modest.

248

As expected, we found that adverse events were more commonly reported with DOT than with SAT. DOT provides more opportunities for health workers to directly ask about and screen for potential side effects. It is also possible that PLHIV had a lower threshold for reporting potential side effects when face-to-face with a health worker than when prompted to so via IVR phone calls. Given the similar treatment completion rates between DOT and SAT, it is unlikely serious adverse events were more likely to be reported with one vs. the other.

255

A strength of this study was its pragmatic nature, including management of adverse events by routine healthcare providers. We therefore provide some of the first real-world evidence of 3HP adverse event occurrence from a clinical setting in a high-burden country. Limitations include the lack of a formal cost analysis of adverse event management and the possibility that people included in our study were more carefully screened for adverse events than would typically occur in the absence of a research study. As such, while we may overestimate the frequency of adverse events, management of those events including decisions to withhold or discontinue 3HP, may have been more careful.

263

In conclusion, this analysis of a pragmatic implementation trial in a large HIV clinic in Kampala, Uganda,
 reaffirms the safety of 3HP, with only one in six participants reporting an adverse event and fewer than

12

1% requiring permanent treatment discontinuation. These data also confirm that routine clinical staff can effectively manage 3HP-related adverse events. These data can be useful to National TB Programs and other implementing partners as they plan resources to support broader roll-out of short-course TPT, including an understanding of the potential additional time required and/or training needed for healthcare staff to manage 3HP-related adverse events and the potential additional costs for anticipated laboratory tests ordered and medications prescribed associated with 3HP-related adverse events. Based on our findings, these additional resources and/or costs associated with 3HP-related adverse events are likely to be low. Future studies of the total cost of 3HP-related adverse event management could provide a more complete picture of the adverse event profile likely to be experienced during programmatic scale-up. Nonetheless, these pragmatic data indicate that 3HP can be delivered safely and effectively in routine settings and can help implementers plan resources for adverse event management. 

## 292 ACKNOWLEDGEMENTS

293 Author contributions: JLK: Formal analysis, Data curation, Writing – Original draft, Writing – Review 294 and editing, Visualization, Project administration; AM: Data curation, Validation, Data curation, Writing – 295 Review and editing, Project administration; HEA: Formal analysis, Data curation, Writing - Original draft, 296 Writing – Review and editing; LA: Data curation, Writing – Review and editing; FW: Data curation, Writing 297 - Review and editing; JN: Data curation, Writing - Review and editing; CAB: Project administration, 298 Writing – Review and editing; NK: Conceptualization, Methodology, Supervision, Writing – Review and 299 editing: AK: Conceptualization, Methodology, Investigation, Supervision, Writing – Review and editing: 300 DWD: Conceptualization, Methodology, Investigation, Supervision, Project Administration, Writing -301 Review and editing: AC: Conceptualization, Methodology, Investigation, Supervision, Project 302 Administration, Funding acquisition, Writing – Review and editing; FS: Conceptualization, Methodology, 303 Investigation, Supervision, Project Administration, Resource, Writing - Review and editing. 304 Acknowledgements: The authors thank the administration, staff, and patients at the Mulago ISS clinic 305 for their time and participation, and the research administration of the Infectious Diseases Research 306 Collaboration (IDRC) and Walimu. 307 Data availability: Data not publicly available. 308 **Funding/support:** The study was supported by the National Heart Lung and Blood Institute of the U.S. 309 National Institutes of Health under award number R01HL144406 (AC).

310 **Financial Disclosure:** None reported.

- 311
- 312
- 313
- 314
- 315
- 316
- 317

## 318 **REFERENCES**

- The End TB Strategy: Global strategy and targets for tuberculosis prevention, care and control after
   2015. World Health Organization; 2014.
- Millington KA, White RG, Lipman M, McQuaid CF, Hauser J, Wooding V, et al. The 2023 UN highlevel meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis. The Lancet Respiratory Medicine. 2024 Jan;12(1):10–3.
- Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz
   Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015/06/18 ed. 2015 Oct 15;61(8):1322–7.
- Farenc C, Doroumian S, Cantalloube C, Perrin L, Esposito V, Cieren-Puiseux, et al. Rifapentine
   Once-Weekly Dosing Effect on Efavirenz, Emtricitabine and Tenofovir Pharmacokinetics. In Boston,
   MA, USA; 2014.
- Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA, et al. Pharmacokinetic
   interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2013/12/18
   ed. 2014 Apr;69(4):1079–85.
- Booley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. The Lancet HIV. 2020 Jun;7(6):e401–9.
- Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, et al. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. Denkinger CM, editor. PLoS Med. 2024 Feb 20;21(2):e1004356.
- Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, et al. Protocol for the 3HP
   Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies
   for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
   Implement Sci. 2020/08/14 ed. 2020 Aug 12;15(1):65.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. U.S.
   DEPARTMENT OF HEALTH AND HUMAN SERVICES; 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic applications/ctc.htm
- Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High Rate of Treatment
   Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent
   Mycobacterium tuberculosis Infection. Clin Infect Dis. 2017/06/03 ed. 2017 Oct 1;65(7):1085–93.
- 11. Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, et al. Symptoms and Systemic
   Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for
   Latent Tuberculosis Infection. Clinical Infectious Diseases. 2023 Jun 16;76(12):2090–7.
- Rahman MT, Hossain F, Banu RS, Islam MS, Alam S, Faisel AJ, et al. Uptake and Completion of
   Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in
   Bangladesh: A Community-Based Implementation Study. Trop Med Infect Dis. 2023 Dec 20;9(1):4.

- 13. Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual
- 357 Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial. Ann Intern
- 358 Med [Internet]. 2021/08/24 ed. 2021 Aug 24; Available from:
- 359 https://www.ncbi.nlm.nih.gov/pubmed/34424730
- 360 14. Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-administered Versus
- 361 Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis
- 362 Infection: A Randomized Trial. Ann Intern Med. 2017/11/09 ed. 2017 Nov 21;167(10):689–97.

363